PRKCA and Alzheimer disease: Given that the parent analogue (Aplog-1) of 1 can activate PKCδ [22] and 1 binds potently to the PKCα-C1A and PKCε-C1B domains [23], 1 is a promising substitute for bryo-1 as a therapeutic drug lead for AD.